Ion Beam Applications SA IBA (GB:0GZK) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Ion Beam Applications SA (IBA) is set to enhance its partnership with the University of Pennsylvania by installing two Proteus® ONE proton therapy solutions at the Penn Presbyterian Medical Center, aiming to start patient treatments in 2027. This move, including a maintenance contract, reinforces IBA’s position as a leading provider of advanced cancer treatment technologies. The University of Pennsylvania, having already treated over 10,000 patients with IBA’s technology, is expanding its proton therapy services to improve clinical availability and patient treatment efficiency.
For further insights into GB:0GZK stock, check out TipRanks’ Stock Analysis page.
